## References

## S-214

- 1. InterQual® Level of Care Criteria 2014, Acute Care Adult, McKesson Health Solutions, LLC
- Kanate A, Pasquini M, Parameswaran, et al. Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. World J Stem Cells. 2014;6(2):69-81
- 3. Li D, Zhu H, Dou L, et al. Efficacy of allogenic hematopoietic stem cell transplantation in intermediate-risk acute myeloid leukemia adult patients in first complete remission: A meta-analysis of prospective studies. *PLoS ONE*. 2015;1-17.
- 4. Versluis J, Hazenberg CLE, van Putten W, et al. Post-remission treatment with allogenic stem Cell transplantation improves outcome in patients aged 60 years and older with acute myeloid leukemia in first remission. *ASH*. 2014;321.
- 5. Stelljes M, Krug U, et al. T. Allogeneic Transplantation Versus Chemotherapy as Post remission Therapy for Acute Myeloid Leukemia: A Prospective Matched Pairs Analysis. *J of C Onc.* 2014;32(4):288-296.
- 6. American Cancer Society. What's New in Acute Myeloid Leukemia Research and Treatment? Revised February 22, 2016.
- Ikegawa S, Doki N, Kurosawa S, et al. Allogeneic hematopoietic stem cell transplant overcomes poor prognosis of acute myeloid leukemia with myelodysplasia-related changes. *Leuk Lymphoma*. 2015;57:76-86
- 8. NCCN Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia version 3.2018. Issued November 30, 2018.